Cited by 661Antifungal resistance and susceptibilityFungal Infections and StudiesFungal Plant Pathogen Control

The DOI matches its Crossref record; 159 of the 160 references it cites were found in a registry or an index.

Fluconazole: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Superficial and Systemic Mycoses

Grant, Susan M., Clissold, Stephen P.·1990·Drugs

DOI 10.2165/00003495-199039060-00006

Open this paper in CoChat — free account

Abstract

Fluconazole is a bis-triazole antifungal drug with novel pharmacokinetic properties (metabolic stability, relatively high water solubility) which contribute to its therapeutic activity. Clinical experience is limited to a relatively small number of mycoses and, as might be expected at this early stage of development, optimal dosage and duration of treatment for some serious mycoses is not yet established. Further study to evaluate higher dosages and to establish the efficacy of fluconazole relative to more established antifungal agents is required. In patients with oropharyngeal or oesophageal candidiasis, fluconazole produces rapid relief and eradicates the yeast in 50 to 90% of patients. Relapse of oral infection is common in chronically immunocompromised patients regardless of the antifungal used, and adequate primary therapy plus long term prophylaxis appears necessary in patients with AIDS. A single oral dose of fluconazole was comparable to standard topical azole therapy in women with acute vaginal candidiasis. Preliminary reports of success against deep-seated candidiasis are encouraging; moreover, experience in noncomparative clinical trials suggests that fluconazole 200 to 400mg once daily resolves infection in the majority of seriously ill patients. Clinical improvement has been reported in a few cases of pulmonary Aspergillus infection but the overall efficacy of conventional dosages of fluconazole in this mycosis has not been as impressive. Early experience in coccidioidosis, predominantly meningitis, suggests a beneficial clinical effect with oral fluconazole in this difficult to treat mycosis but relapse remains a problem. Fluconazole is a promising treatment of cryptococcal meningitis. The rate of clinical resolution and eradication of Cryptococcus neoformans from cerebrospinal fluid has been similar between fluconazole and amphotericin B treatment groups in comparative trials. Comparative trials of maintenance therapy indicate a similar low rate of relapse among patients given oral fluconazole once daily and intravenous amphotericin B once weekly. However, these results are preliminary and further study is required. Fluconazole has been well tolerated to date but wider clinical experience is needed, especially with regard to the rate occurrence of hepatotoxicity and exfoliative skin reactions. The promising clinical response of patients with various forms of candidiasis or cryptococcosis--together with convenient administration regimens--recommends fluconazole as a useful addition to currently available systemic antifungal therapies, in particular for the treatment of mycoses in patients with AIDS.

Integrity signals

Registry

Crossref · 10.2165/00003495-199039060-00006

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Azole antifungal agents: Emphasis on new triazoles
Saag, M. S., & Dismukes, W. E. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.1.1 · Cited by 474
Cryptococcal Meningitis in Patients with AIDS
Dismukes, W. E. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/157.4.624 · Cited by 389
Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans
Humphrey, M., Jevons, S., & Tarbit, M. H. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.5.648 · Cited by 367
Itraconazole
Grant, S., & Clissold, S. P. (1989) · Drugs · doi:10.2165/00003495-198937030-00003 · Cited by 362
Self-citation
Pharmacokinetics of itraconazole following oral administration to normal volunteers
Hardin, T. C., Graybill, J. R., Fetchick, R. J., Woestenborghs, R. J. H., Rinaldi, M. G., & Kuhn, J. G. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.9.1310 · Cited by 299
Ketoconazole
Heel, R. C., Brogden, R. N., Carmine, A., Morley, P. A., Speight, T. M., & Avery, G. S. (1982) · Drugs · doi:10.2165/00003495-198223010-00001 · Cited by 277
Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes
Yoshida, Y., & Aoyama, Y. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90694-0 · Cited by 247
Pharmacokinetic profile of orally administered itraconazole in human skin
Cauwenbergh, G. F. M. J., Degreef, H. J., Heykants, J., Woestenborghs, R., Rooy, P. V., & Haeverans, K. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)70037-7 · Cited by 245
Activity of Orally, Topically, and Parenterally Administered Itraconazole in the Treatment of Superficial and Deep Mycoses: Animal Models
Cutsem, J. V., Gerven, F. V., & Janssen, P. A. J. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_1.s15 · Cited by 212
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis
Savani, D. V., Perfect, J. R., Cobo, L. M., & Durack, D. T. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.1.6 · Cited by 202

Show all 160 references

Sorted by citations

Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Infections in solid-organ transplant recipients
Patel, R., & Paya, C. V. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.1.86 · Cited by 680
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Current Perspectives on Ophthalmic Mycoses
Thomas, P. A. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.4.730-797.2003 · Cited by 462
Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
Brüggemann, R. J. M., Alffenaar, J. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009) · Clinical Infectious Diseases · doi:10.1086/598327 · Cited by 458
The Clinical Pharmacokinetics of Itraconazole: An Overview
Heykants, J., Peer, A. V., de Velde, V. V., Rooy, P. V., Meuldermans, W., Lavrijsen, K., Woestenborghs, R., Cutsem, J. V., & Cauwenbergh, G. F. M. J. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02296.x · Cited by 405
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 418
Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Antifungal agents: An overview. Part I
Gupta, A. K., Sauder, D. N., & Shear, N. H. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81495-8 · Cited by 370
Effects of Food on Clinical Pharmacokinetics
Singh, B. N. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937030-00003 · Cited by 366
Chromoblastomycosis
Queiroz-Telles, F., de Hoog, S., Santos, D. W. C. L., Salgado, C. G., Vicente, V. A., Bonifaz, A., Roilides, E., Xi, L., Azevedo, C. D. M. P. E. S., da Silva, M. B., et al. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00032-16 · Cited by 360
Antifungal Agents
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN
Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezequel, S. G., Nedderman, A. N. R., Smith, D. A., Walker, D. K., & Wood, N. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.731 · Cited by 330
Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment
Queiroz‐Telles, F., Esterre, P., Blanco, M. P., Vitale, R. G., Salgado, C. G., & Bonifáz, A. (2008) · Medical Mycology · doi:10.1080/13693780802538001 · Cited by 330
REVIEW ARTICLE: Toenail onychomycosis: an important global disease burden
Thomas, J., Jacobson, G. A., Narkowicz, C., Peterson, G. M., Burnet, H., & Sharpe, C. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01107.x · Cited by 329
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Preparation and Characterization of Nanofibers Containing Amorphous Drug Dispersions Generated by Electrostatic Spinning
Verreck, G., Chun, I., Peeters, J., Rosenblatt, J., & Brewster, M. E. (2003) · Pharmaceutical Research · doi:10.1023/a:1023450006281 · Cited by 312
Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 300
Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis
Galgiani, J. N., Catanzaro, A., Cloud, G. A., Johnson, R. H., Williams, P. L., Mirels, L. F., Nassar, F., Lutz, J. E., Stevens, D. A., Sharkey, P. K., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-9-200011070-00009 · Cited by 294
Pharmacology of Itraconazole
De Beule, K., & Van Gestel, J. (2001) · Drugs · doi:10.2165/00003495-200161001-00003 · Cited by 283
Systemic Antifungal Agents
Albengres, E., Lou, L., & Tillement, J. P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 279
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin
Backman, J. T., Kivistö, K. T., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050420 · Cited by 266
Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients
Glasmacher, A. G., Prentice, A. G., Gorschlüter, M., Engelhart, S., Hahn, C., Djulbegović, B., & Schmidt‐Wolf, I. G. H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.052 · Cited by 263
Introduction to Antifungal Drugs
Dismukes, W. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313748 · Cited by 262
Clinical Pharmacokinetics of Fluconazole
Debruyne, D., & Ryckelynck, J. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324010-00002 · Cited by 256
Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion—part I
Verreck, G., Six, K., den Mooter, G. V., Baert, L., Peeters, J., & Brewster, M. E. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00591-4 · Cited by 252
Systemically Administered Antifungal Agents
Lyman, C. A., & Walsh, T. J. (1992) · Drugs · doi:10.2165/00003495-199244010-00002 · Cited by 234
Clinically Significant Drug Interactions with Cyclosporin
Campana, C., Regazzi, M. B., Buggia, I., & Molinaro, M. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630020-00004 · Cited by 228
Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics
Willems, L., van der Geest, R., & Beule, K. D. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00338.x · Cited by 226
Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers
Barone, J. A., Koh, J.-S., Bierman, R. H., Colaizzi, J. L., Swanson, K. A., Gaffar, M. C., Moskovitz, B. L., Mechlinski, W., & de Velde, V. V. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.4.778 · Cited by 226
Candida Urinary Tract Infections—Treatment
Fisher, J. F., Sobel, J. D., Kauffman, C. A., & Newman, C. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir112 · Cited by 219
Azole Antifungal Agents
Bodey, G. P. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.supplement_1.s161 · Cited by 216
Enhanced Bioavailability of Itraconazole in Hydroxypropylβ-Cyclodextrin Solution versus Capsules in Healthy Volunteers
Barone, J. A., Moskovitz, B. L., Guarnieri, J. A., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1862 · Cited by 207
Itraconazole therapy in aspergillosis: Study in 49 patients
Dupont, B. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(90)70263-h · Cited by 196
Fluconazole
Goa, K. L., & Barradell, L. B. (1995) · Drugs · doi:10.2165/00003495-199550040-00007 · Cited by 195
Antimicrobial Peptide Synergies for Fighting Infectious Diseases
Mhlongo, J. T., Waddad, A. Y., Alberício, F., & de la Torre, B. G. (2023) · Advanced Science · doi:10.1002/advs.202300472 · Cited by 201
Azole antifungal agents
(2011) · Springer eBooks · doi:10.1007/springerreference_40367 · Cited by 191
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
Winston, D. J., Hathorn, J. W., Schuster, M. G., Schiller, G. J., & Territo, M. C. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00457-x · Cited by 189
Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole
Malík, R., Wigney, D. I., Muir, D. B., Gregory, D., & Love, D. N. (1992) · Medical Mycology · doi:10.1080/02681219280000181 · Cited by 186
Voriconazole: A New Triazole Antifungal
Sabo, J., & Abdel‐Rahman, S. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19237 · Cited by 184
Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study
Lazarus, H. M., Blumer, J. L., Yanovich, S., Schlamm, H. T., & Romero, A. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011445 · Cited by 178
Itraconazole Prophylaxis for Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection: Randomized, Placebo‐Controlled, Double‐Blind Study
McKinsey, D. S., Wheat, L. J., Cloud, G. A., Pierce, M. A., Black, J. R., Bamberger, D. M., Goldman, M., Thomas, C. J., Gutsch, H. M., Moskovitz, B. L., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514744 · Cited by 177
Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia
Clancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., & Nguyen, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3171-3177.2005 · Cited by 175
Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole
Zimmermann, T., Yeates, R. A., Laufen, H., Pfaff, G., & Wildfeuer, A. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00199879 · Cited by 172
Optimisation of Itraconazole Therapy Using Target Drug Concentrations
Poirier, M., & CHEYMOL, G. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835060-00004 · Cited by 172
Functional Genomic Analysis of Fluconazole Susceptibility in the Pathogenic Yeast Candida glabrata : Roles of Calcium Signaling and Mitochondria
Kaur, R., Castaño, I., & Cormack, B. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1600-1613.2004 · Cited by 167
The spectrum of orbital aspergillosis: a clinicopathological review
Levin, L. A., Avery, R. K., Shore, J. W., Woog, J. J., & Baker, A. S. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80004-x · Cited by 165
Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.
Back, D., & Tjia, J. F. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03963.x · Cited by 163
Randomized Trial of Fluconazole versus Nystatin for the Prophylaxis of Candida Infection following Liver Transplantation
Lumbreras, C., Cuervas‐Mons, V., Jara, P., del Palacio, A., Turrión, V. S., Barrios, C., Moreno, E., Noriega, A. R., & Paya, C. V. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.3.583 · Cited by 160
Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease
Mouy, R., Veber, F., Blanche, S., Donadieu, J., Brauner, R., Levron, J., Griscelli, C., & Fischer, A. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82023-2 · Cited by 158
Enhanced In Vivo Absorption of Itraconazole via Stabilization of Supersaturation Following Acidic-to-Neutral pH Transition
Miller, D. A., DiNunzio, J. C., Yang, W., McGinity, J. W., & Williams, R. O. (2008) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040801929273 · Cited by 161
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome
Ghannoum, M. A., Rex, J. H., & Galgiani, J. N. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.3.489-495.1996 · Cited by 159
Itraconazole
Haria, M., Bryson, H. M., & Goa, K. L. (1996) · Drugs · doi:10.2165/00003495-199651040-00006 · Cited by 158
Pulmonary Aspergillosis and Invasive Disease in AIDS
Mylonakis, E. E., Barlam, T. F., Flanigan, T., & Rich, J. D. (1998) · CHEST Journal · doi:10.1378/chest.114.1.251 · Cited by 156
Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole
Doncker, P. D. (1996) · Archives of Dermatology · doi:10.1001/archderm.132.1.34 · Cited by 156
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
Louie, A., Drusano, G. L., Banerjee, P., Liu, Q.-F., Liu, W., Kaw, P., Shayegani, M., Taber, H., & Miller, M. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1105 · Cited by 154
Update on Candida krusei , a potential multidrug-resistant pathogen
Jamiu, A. T., Albertyn, J., Sebolai, O. M., & Pohl, C. H. (2020) · Medical Mycology · doi:10.1093/mmy/myaa031 · Cited by 173
Antifungal Agents Used for Deep-Seated Mycotic Infections
Terrell, C. L., & Hughes, C. E. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60281-x · Cited by 152
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
Murphy, M., Bernard, E. M., Ishimaru, T., & Armstrong, D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.696 · Cited by 151
Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant
Hiemenz, J., Cagnoni, P. J., Simpson, D., Devine, S. M., Chao, N. J. A., Keirns, J. J., Lau, W. M., Facklam, D., & Buell, D. N. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1331-1336.2005 · Cited by 150
Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety
Purkins, L., Wood, N., Greenhalgh, K., Allen, M. J., & Oliver, S. D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01993.x · Cited by 148
Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses
Debruyne, D. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733010-00005 · Cited by 151
Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens
Supparatpinyo, K., Nelson, K. E., Merz, W. G., Breslin, B. J., Cooper, C. R., Kamwan, C., & Sirisanthana, T. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2407 · Cited by 147
Tinea capitis
Gupta, A. K., & Summerbell, R. C. (2000) · Medical Mycology · doi:10.1080/mmy.38.4.255.287 · Cited by 146
Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection
Bräutigam, M., Nolting, S., Schopf, R. E., & Weidinger, G. (1995) · BMJ · doi:10.1136/bmj.311.7010.919 · Cited by 143
Pharmacokinetic Drug Interactions with Antimicrobial Agents
Gillum, J. G., Israel, D. S., & Polk, R. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325060-00005 · Cited by 143
Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy
Singh, N. (2000) · Clinical Infectious Diseases · doi:10.1086/313943 · Cited by 140
Pharmacokinetics of fluconazole in pediatric patients
Brammer, K. W., & Coates, P. E. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01974613 · Cited by 139
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia
Rodríguez-Tudela, J. L., Almirante, B., Rodríguez-Pardo, D., Laguna, F., Donnelly, J. P., Mouton, J. W., Pahissa, A., & Cuenca-Estrella, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-07 · Cited by 137
Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis
Catanzaro, A., Galgiani, J. N., Levine, B. E., Sharkey, P. K., Fierer, J., Stevens, D. A., Chapman, S. W., & Cloud, G. A. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80371-4 · Cited by 137
Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide
Skov, M., Main, K. M., Ib, S., Müller, J., Koch, C., & Lanng, S. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00248002 · Cited by 136
Effect of omeprazole on the pharmacokinetics of itraconazole
Jaruratanasirikul, S., & Sriwiriyajan, S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050438 · Cited by 135
Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects
Lebrun‐Vignes, B., Archer, V. C., Diquet, B., Levron, J. C., Chosidow, O., Puech, A. J., & Warot, D. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01372.x · Cited by 129
Therapy of Skin, Hair and Nail Fungal Infections
Hay, R. J. (2018) · Journal of Fungi · doi:10.3390/jof4030099 · Cited by 128
Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole
Jaruratanasirikul, S., & Kleepkaew, A. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050280 · Cited by 128
Voriconazole for Invasive Bone Aspergillosis: A Worldwide Experience of 20 Cases
Mouas, H., Lutsar, I., Dupont, B., Fain, O., Herbrecht, R., Lescure, F.-X., Lortholary, O., & The Voriconazole/Bone Invasive Aspergillosis Study Group (2005) · Clinical Infectious Diseases · doi:10.1086/428734 · Cited by 126
RECENT PROGRESS AND CURRENT PROBLEMS IN TREATMENT OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS
Walsh, T. J., Hiemenz, J. W., & Anaissie, E. J. (1996) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70303-2 · Cited by 125
Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis
Louie, A., Baltch, A. L., Smith, R. P., Franke, M. A., Ritz, W. J., Singh, J. K., & Gordon, M. A. (1994) · Infection and Immunity · doi:10.1128/iai.62.7.2761-2772.1994 · Cited by 120
Safety and pharmacokinetics of fluconazole in children with neoplastic diseases
Lee, J. W., Seibel, N. L., Amantea, M., Whitcomb, P., Pizzo, P. A., & Walsh, T. J. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81975-4 · Cited by 120
Treatment of Blastomycosis With Itraconazole in 112 Dogs
Legendre, A. Μ., Rohrbach, B. W., Toal, R. L., Rinaldi, M. G., Grace, L. L., & Jones, J. B. (1996) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.1996.tb02082.x · Cited by 120
Characterization of Solid Dispersions of Itraconazole and Hydroxypropylmethylcellulose Prepared by Melt Extrusion, Part II
Six, K., Berghmans, H., Leuner, C., Dressman, J., Werde, K. V., Mullens, J., Benoist, L., Thimon, M., Meublat, L., Verreck, G., et al. (2003) · Pharmaceutical Research · doi:10.1023/a:1024414423779 · Cited by 120
Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States
Abuhelwa, A. Y., Foster, D. J. R., Mudge, S., Hayes, D., & Upton, R. N. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00973-15 · Cited by 119
Antifungal Agents. Part II. The Azoles
Terrell, C. L. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.1.78 · Cited by 119
Rationale for Combination Antifungal Therapy
Lewis, R. E., & Kontoyiannis, D. P. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.149s.34505 · Cited by 116
Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.
Stevens, D. A., & Lee, J. Y. (1997) · PubMed · Cited by 115
PREEMPTIVE PROPHYLAXIS WITH A LIPID PREPARATION OF AMPHOTERICIN B FOR INVASIVE FUNGAL INFECTIONS IN LIVER TRANSPLANT RECIPIENTS REQUIRING RENAL REPLACEMENT THERAPY1
Singh, N., Paterson, D. L., Gayowski, T., Wagener, M. M., & Marino, I. R. (2001) · Transplantation · doi:10.1097/00007890-200104150-00016 · Cited by 112
The search for new triazole antifungal agents
Koltin, Y., & Hitchcock, C. A. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80007-5 · Cited by 110
Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
Martin, M. V., Yates, J. O., & Hitchcock, C. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.13 · Cited by 110
Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL
Böhme, A., Ganser, A., & Hoelzer, D. T. (1995) · Annals of Hematology · doi:10.1007/bf01697985 · Cited by 108
Safety and Tolerability of Fluconazole in Children
Novelli, V. M., & Holzel, H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1955 · Cited by 108
Pharmacokinetics of fluconazole following intravenous and oral administration and body fluid concentrations of fluconazole following repeated oral dosing in horses
Latimer, F. G., Colitz, C. M. H., Campbell, N. B., & Papich, M. G. (2001) · American Journal of Veterinary Research · doi:10.2460/ajvr.2001.62.1606 · Cited by 107
A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia
Malik, I. A., Moid, I., Aziz, Z., Khan, S., & Suleman, M. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00326-x · Cited by 106
Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs
den Mooter, G. V., Weuts, I., Ridder, T. D., & Blaton, N. M. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.02.025 · Cited by 109
Yeast in the Urine: Solutions for a Budding Problem
Fisher, J. F., Newman, C. L., & Sobel, J. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.183 · Cited by 101
Abc1p Is a Multidrug Efflux Transporter That Tips the Balance in Favor of Innate Azole Resistance in Candida krusei
Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01095-08 · Cited by 100
Antifungal agents and liver toxicity: a complex interaction
Tverdek, F. P., Kofteridis, D. P., & Kontoyiannis, D. P. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1199272 · Cited by 102

Authors: Grant, S. M., & Clissold, S. P.
ORCID: Grant, Susan M.
Venue: Drugs
Publisher: Springer Science and Business Media LLC
Published: 1990-06
Volume: 39
Issue: 6
Pages: 877-916
ISSN: 0012-6667 (ISSN-L)
DOI: 10.2165/00003495-199039060-00006
OpenAlex: W1971920484
Cited by: 661
References: 160
Citations by year: 2026: 6 · 2025: 7 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 11 · 2020: 9 · 2019: 10 · 2018: 8 · 2017: 9 · 2016: 12 · 2015: 12 · 2014: 13 · 2013: 14 · 2012: 12
FWCI: 25.31
Type: journal article
Language: en
Open access: closed
Locations: Drugs (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords: antifungal agents, candidiasis, cryptococcosis, cryptococcal meningitis, AIDS, pulmonary aspergillosis, coccidioidomycosis, vaginal candidiasis, oropharyngeal candidiasis, drug metabolism, pharmacokinetics, hepatotoxicity, drug interactions, adverse drug reactions
MeSH terms: Animals, Fungi, Humans, Mycoses, Fluconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fluconazole: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Superficial and Systemic Mycoses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks